All In MedTech

Device Trial Radar · NCT07907055

PAUL® Glaucoma Implant Safety and Effectiveness Study

PROSPECTIVE MULTICENTER STUDY OF THE SAFETY AND EFFECTIVENESS OF THE PAUL® GLAUCOMA IMPLANT

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

May 1, 2028

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Clinical Research Consultants, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 30, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, multicenter clinical study is designed to evaluate the safety and effectiveness of the PAUL® Glaucoma Implant in adult patients with refractory glaucoma. Effectiveness will be assessed by measuring the reduction in intraocular pressure (IOP). Study results will support regulatory submissions to the U.S. Food and Drug Administration (FDA) and may also be used to support regulatory submissions and postmarketing surveillance activities in other countries.

Conditions

  • Refractory Glaucoma

Interventions

  • PAUL® Glaucoma ImplantDevice

    The PAUL® Glaucoma Implant is an aqueous drainage device surgically implanted to facilitate aqueous humor drainage and reduce intraocular pressure in patients with refractory glaucoma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Achieving ≥20% Reduction in Mean Diurnal Intraocular Pressure (DIOP)Time frame: Baseline to 12 months postoperatively

3 more outcomes with a free account

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.